Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking mycn amplification

D. Plantaz, J. Vandesompele, N. Van Roy, M. Astowska, N. Bown, V. Combaret, M. C. Favrot, O. Delattre, J. Michon, J. Bénard, O. Hartmann, J. C. Nicholson, F. M. Ross, C. Brinkschmidt, G. Laureys, H. Caron, K. K. Matthay, Burt G.F. Feuerstein, F. Speleman

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

We have studied the occurrence and association of 11q deletions with other chromosomal imbalances in Stage 4 neuroblastomas. To this purpose we have performed comparative genomic hybridization (CGH) analysis on 50 Stage 4 neuroblastomas and these data were analyzed together with those from 33 previously published cases. We observed a high incidence of 11q deletion in Stage 4 neuroblastoma without MYCN amplification (59%) whereas 11q loss was only observed in 15% of neuroblastomas with MYCN-amplification (p = 0.0002) or 11% of cases with 1p deletion detected by CGH (p = 0.0001). In addition, 11q loss showed significant positive correlation with 3p loss (p = 0.0002). Event-free survival was poor and not significantly different for patients with or without 11q deletion. Our study provides further evidence that Stage 4 neuroblastomas with 11q deletions represent a distinct genetic subgroup that typically shows no MYCN-amplification nor 1p deletion. Moreover, it shows that neuroblastomas with 11q deletion also often present 3p deletion. This genetic subgroup shows a similar poor prognosis as MYCN amplified 4 neuroblastomas.

Original languageEnglish (US)
Pages (from-to)680-686
Number of pages7
JournalInternational Journal of Cancer
Volume91
Issue number5
DOIs
StatePublished - Mar 1 2001
Externally publishedYes

Fingerprint

Comparative Genomic Hybridization
Neuroblastoma
Neoplasms
Disease-Free Survival
Incidence

Keywords

  • 11q deletion
  • 1p deletion
  • Comparative genomic hybridization
  • Genetic subgroup
  • MYCN
  • Stage 4 neuroblastoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking mycn amplification. / Plantaz, D.; Vandesompele, J.; Van Roy, N.; Astowska, M.; Bown, N.; Combaret, V.; Favrot, M. C.; Delattre, O.; Michon, J.; Bénard, J.; Hartmann, O.; Nicholson, J. C.; Ross, F. M.; Brinkschmidt, C.; Laureys, G.; Caron, H.; Matthay, K. K.; Feuerstein, Burt G.F.; Speleman, F.

In: International Journal of Cancer, Vol. 91, No. 5, 01.03.2001, p. 680-686.

Research output: Contribution to journalArticle

Plantaz, D, Vandesompele, J, Van Roy, N, Astowska, M, Bown, N, Combaret, V, Favrot, MC, Delattre, O, Michon, J, Bénard, J, Hartmann, O, Nicholson, JC, Ross, FM, Brinkschmidt, C, Laureys, G, Caron, H, Matthay, KK, Feuerstein, BGF & Speleman, F 2001, 'Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking mycn amplification', International Journal of Cancer, vol. 91, no. 5, pp. 680-686. https://doi.org/10.1002/1097-0215(200002)9999:9999<::AID-IJC1114>3.0.CO;2-R
Plantaz, D. ; Vandesompele, J. ; Van Roy, N. ; Astowska, M. ; Bown, N. ; Combaret, V. ; Favrot, M. C. ; Delattre, O. ; Michon, J. ; Bénard, J. ; Hartmann, O. ; Nicholson, J. C. ; Ross, F. M. ; Brinkschmidt, C. ; Laureys, G. ; Caron, H. ; Matthay, K. K. ; Feuerstein, Burt G.F. ; Speleman, F. / Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking mycn amplification. In: International Journal of Cancer. 2001 ; Vol. 91, No. 5. pp. 680-686.
@article{7ad0dff3215f44f7b35a7c84ce7fb894,
title = "Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking mycn amplification",
abstract = "We have studied the occurrence and association of 11q deletions with other chromosomal imbalances in Stage 4 neuroblastomas. To this purpose we have performed comparative genomic hybridization (CGH) analysis on 50 Stage 4 neuroblastomas and these data were analyzed together with those from 33 previously published cases. We observed a high incidence of 11q deletion in Stage 4 neuroblastoma without MYCN amplification (59{\%}) whereas 11q loss was only observed in 15{\%} of neuroblastomas with MYCN-amplification (p = 0.0002) or 11{\%} of cases with 1p deletion detected by CGH (p = 0.0001). In addition, 11q loss showed significant positive correlation with 3p loss (p = 0.0002). Event-free survival was poor and not significantly different for patients with or without 11q deletion. Our study provides further evidence that Stage 4 neuroblastomas with 11q deletions represent a distinct genetic subgroup that typically shows no MYCN-amplification nor 1p deletion. Moreover, it shows that neuroblastomas with 11q deletion also often present 3p deletion. This genetic subgroup shows a similar poor prognosis as MYCN amplified 4 neuroblastomas.",
keywords = "11q deletion, 1p deletion, Comparative genomic hybridization, Genetic subgroup, MYCN, Stage 4 neuroblastoma",
author = "D. Plantaz and J. Vandesompele and {Van Roy}, N. and M. Astowska and N. Bown and V. Combaret and Favrot, {M. C.} and O. Delattre and J. Michon and J. B{\'e}nard and O. Hartmann and Nicholson, {J. C.} and Ross, {F. M.} and C. Brinkschmidt and G. Laureys and H. Caron and Matthay, {K. K.} and Feuerstein, {Burt G.F.} and F. Speleman",
year = "2001",
month = "3",
day = "1",
doi = "10.1002/1097-0215(200002)9999:9999<::AID-IJC1114>3.0.CO;2-R",
language = "English (US)",
volume = "91",
pages = "680--686",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking mycn amplification

AU - Plantaz, D.

AU - Vandesompele, J.

AU - Van Roy, N.

AU - Astowska, M.

AU - Bown, N.

AU - Combaret, V.

AU - Favrot, M. C.

AU - Delattre, O.

AU - Michon, J.

AU - Bénard, J.

AU - Hartmann, O.

AU - Nicholson, J. C.

AU - Ross, F. M.

AU - Brinkschmidt, C.

AU - Laureys, G.

AU - Caron, H.

AU - Matthay, K. K.

AU - Feuerstein, Burt G.F.

AU - Speleman, F.

PY - 2001/3/1

Y1 - 2001/3/1

N2 - We have studied the occurrence and association of 11q deletions with other chromosomal imbalances in Stage 4 neuroblastomas. To this purpose we have performed comparative genomic hybridization (CGH) analysis on 50 Stage 4 neuroblastomas and these data were analyzed together with those from 33 previously published cases. We observed a high incidence of 11q deletion in Stage 4 neuroblastoma without MYCN amplification (59%) whereas 11q loss was only observed in 15% of neuroblastomas with MYCN-amplification (p = 0.0002) or 11% of cases with 1p deletion detected by CGH (p = 0.0001). In addition, 11q loss showed significant positive correlation with 3p loss (p = 0.0002). Event-free survival was poor and not significantly different for patients with or without 11q deletion. Our study provides further evidence that Stage 4 neuroblastomas with 11q deletions represent a distinct genetic subgroup that typically shows no MYCN-amplification nor 1p deletion. Moreover, it shows that neuroblastomas with 11q deletion also often present 3p deletion. This genetic subgroup shows a similar poor prognosis as MYCN amplified 4 neuroblastomas.

AB - We have studied the occurrence and association of 11q deletions with other chromosomal imbalances in Stage 4 neuroblastomas. To this purpose we have performed comparative genomic hybridization (CGH) analysis on 50 Stage 4 neuroblastomas and these data were analyzed together with those from 33 previously published cases. We observed a high incidence of 11q deletion in Stage 4 neuroblastoma without MYCN amplification (59%) whereas 11q loss was only observed in 15% of neuroblastomas with MYCN-amplification (p = 0.0002) or 11% of cases with 1p deletion detected by CGH (p = 0.0001). In addition, 11q loss showed significant positive correlation with 3p loss (p = 0.0002). Event-free survival was poor and not significantly different for patients with or without 11q deletion. Our study provides further evidence that Stage 4 neuroblastomas with 11q deletions represent a distinct genetic subgroup that typically shows no MYCN-amplification nor 1p deletion. Moreover, it shows that neuroblastomas with 11q deletion also often present 3p deletion. This genetic subgroup shows a similar poor prognosis as MYCN amplified 4 neuroblastomas.

KW - 11q deletion

KW - 1p deletion

KW - Comparative genomic hybridization

KW - Genetic subgroup

KW - MYCN

KW - Stage 4 neuroblastoma

UR - http://www.scopus.com/inward/record.url?scp=0035283744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035283744&partnerID=8YFLogxK

U2 - 10.1002/1097-0215(200002)9999:9999<::AID-IJC1114>3.0.CO;2-R

DO - 10.1002/1097-0215(200002)9999:9999<::AID-IJC1114>3.0.CO;2-R

M3 - Article

VL - 91

SP - 680

EP - 686

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -